Congenital Abnormalities: Clinical Trials

6 trials for Congenital Abnormalities, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 suspended. 6 Phase 2, 2 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Suspended 6
Phase 12Suspended 2
Phase 31Suspended 1

Follow Congenital Abnormalities: new trials by email Literature Review of Congenital Abnormalities trials Research Report on Congenital Abnormalities

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome
Psilocybin, 1.5 mg - Fragile X Syndrome, Behavior
Phase 2SuspendedNova Mentis Life Science Corp102023-03-282024-05-08
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
Rituximab, Zanubrutinib, Cyclophosphamide - Diffuse Large B Cell Lymphoma, CD79A Gene Mutation
Phase 2SuspendedHenan Cancer Hospital592020-12-252025-04-25
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Emavusertib, Venetoclax - Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Phase 1 / Phase 2SuspendedCuris, Inc.3662020-07-062026-03-19
Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)
ASN-002 - Basal Cell Carcinoma in Basal Cell Nevus Syndrome
Phase 1 / Phase 2SuspendedAscend Biopharmaceuticals Ltd242017-12-012023-02-06
Paracetamol vs Ibuprofen for PDA Closure in Preterm Infants.
Intravenous paracetamol, Intravenous ibuprofen - Ductus Arteriosus Patent, Respiratory Distress Syndrome
Phase 2 / Phase 3SuspendedUniversity of Padova1202017-01-092019-11-04
A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome
STX107 - Fragile X Syndrome
Phase 2SuspendedSeaside Therapeutics, Inc.162011-05-012012-12-20

Narrower conditions

Fragile X Syndrome (2)  ·  Basal Cell Nevus Syndrome (1)  ·  Behavior (1)  ·  Carcinoma, Basal Cell (1)  ·  Cognitive Dysfunction (1)  ·  Ductus Arteriosus, Patent (1)  ·  Hereditary Sensory and Autonomic Neuropathies (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Myelodysplastic Syndromes (1)  ·  Neurobehavioral Manifestations (1)  ·  Premature Birth (1)  ·  Recurrence (1)  ·  Respiratory Distress Syndrome (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6)  ·  Genetic Diseases, Inborn (4)  ·  Heredodegenerative Disorders, Nervous System (3)  ·  Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Nervous System Diseases (3)  ·  Chromosome Disorders (2)  ·  Genetic Diseases, X-Linked (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Intellectual Disability (2)  ·  Neurologic Manifestations (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Sex Chromosome Disorders (2)  ·  X-Linked Intellectual Disability (2)

Interventions

CA-4948 (1)  ·  Cyclophosphamide (1)  ·  Epirubicin (1)  ·  Prednisone (1)  ·  Psilocybin (1)  ·  Rituximab (1)  ·  Vincristine (1)  ·  gusacitinib (1)  ·  venetoclax (1)  ·  zanubrutinib (1)

Sponsors

Ascend Biopharmaceuticals Ltd (1)  ·  Curis, Inc. (1)  ·  Henan Cancer Hospital (1)  ·  Nova Mentis Life Science Corp (1)  ·  Seaside Therapeutics, Inc. (1)  ·  University of Padova (1)

Countries

United States (3)  ·  Italy (2)  ·  Canada (1)  ·  China (1)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Poland (1)  ·  Spain (1)

Top investigators

Anna Bar (1)  ·  Clement Leong (1)  ·  David Crowley, MD (1)  ·  Marvin Hausman, MD (1)  ·  Paola Lago, MD (1)  ·  Yanyan Liu, M.D. Ph.D (1)  ·  Zhihua Yao, M.D. Ph.D (1)

Results publications

PMID 21317433, PMID 22065264, PMID 22611117, PMID 23258386